People · Operator
Named in public records as an officer, director or promoter · active 2015–2019 · Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Front Range Biosciences, Inc. | — | Biotech / Pharma | Series B | $45.0M | $689.5M | 2018 |
| Triton Algae Innovations, Ltd. | — | Biotechnology | Series A | $5.0M | $180.8M | 2015 |
Nicholas Hofmeister at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nicholas Hofmeister on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ephraim Lindenbaum | 1 | 5 |
| Marc Riiska | 1 | 4 |
| Jason Pyle | 1 | 3 |
| Nick Hofmeister | 1 | 2 |
| Stephen Mayfield | 1 | 2 |
| David Wellis | 1 | 1 |
| Len Smith | 1 | 1 |
| Daniel Sachs | 1 | 1 |
| Xun Wang | 1 | 1 |
| William Militello | 1 | 1 |
| Jonathan Vaught | 1 | 1 |
| Douglas Wolford | 1 | 1 |
| Christopher Zalewski | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.